Acute upper gastrointestinal bleeding
Everything NICE has said on risk assessment and management of acute upper gastrointestinal bleeding in people 16 years and older in an interactive flowchart
Search results
689 results
-
-
Abortion care
Everything NICE has said on abortion care in an interactive flowchart.
-
Cervical cancer
Everything NICE has said on screening and managing cervical cancer in an interactive flowchart
-
Cataracts
Everything NICE has said on cataracts in adults in an interactive flowchart
-
Cellulitis and erysipelas – antimicrobial prescribing
Everything NICE has said on antimicrobial prescribing for cellulitis and erysipelas in an interactive flowchart
-
Chronic fatigue syndrome myalgic encephalomyelitis
Everything NICE has said on assessing, diagnosing and managing chronic fatigue syndrome/myalgic encephalomyelitis in an interactive flowchart
-
Induction of labour
Everything NICE has said on inducing labour in an interactive flowchart
-
Smoking cessation in secondary care
Everything NICE has said on helping people to stop smoking in secondary care in an interactive flowchart
-
Stroke
Everything NICE has said on preventing, diagnosing and managing stroke and transient ischaemic attack (TIA) in people over 16 in an interactive flowchart
-
Intermediate care including reablement
Everything NICE has said on referral and assessment for and delivery of intermediate care including reablement in an interactive flowchart
-
Influenza
Everything NICE has said on influenza in an interactive flowchart
-
Gastrointestinal cancers
Everything NICE has said on gastrointestinal cancers in an interactive flowchart
-
Gallstone disease
Everything NICE has said on diagnosing and managing gallstone disease in adults in an interactive flowchart
-
Glaucoma
Everything NICE has said on assessing, treating and managing glaucoma in adults in an interactive flowchart
-
Generalised anxiety disorder
Everything NICE has said on managing generalised anxiety disorder in adults in primary, secondary and community care in an interactive flowchart
-
Harmful sexual behaviour among children and young people
Everything NICE has said on harmful sexual behaviour among children and young people (under 18s or under 25s with special educational needs or a disability) in an interactive flowchart.
-
Hearing loss
Everything NICE has said on hearing loss or impairment in adults in an interactive flowchart
-
Acutely ill patients in hospital
Everything NICE has said on recognising and responding to acute illness in adults in hospital in an interactive flowchart
-
Vitamin D: supplement use in specific population groups
Everything NICE has said on preventing vitamin D deficiency in specific population groups in an interactive flowchart
-
Urogenital conditions
Everything NICE has said on urogenital conditions in an interactive flowchart
-
Urinary incontinence in neurological disease
Everything NICE has said on managing lower urinary tract dysfunction resulting from neurological disease and injury in an interactive flowchart
-
Sepsis
Everything NICE has said on the recognition, diagnosis and early management of sepsis in an interactive flowchart
-
Colorectal cancer
Everything NICE has said on diagnosing and managing colorectal (bowel) cancer in an interactive flowchart
-
Mental health problems in people with learning disabilities
Mental health problems in people with learning disabilities
-
Intrapartum care for women with obstetric complications
Everything NICE has said on intrapartum care for women with obstetric complications in an interactive flowchart
-
Rheumatoid arthritis
Everything NICE has said on managing rheumatoid arthritis in adults in an interactive flowchart
-
Early and locally advanced breast cancer
Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart
-
Neurological conditions
Everything NICE has said on neurological conditions in an interactive flowchart
-
Lower urinary tract symptoms in men
Everything NICE has said on managing lower urinary tract symptoms in men in an interactive flowchart
-
Cystic fibrosis
Everything NICE has said on diagnosing and managing cystic fibrosis in an interactive flowchart
-
myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
NICE has developed a medtech innovation briefing (MIB) on myCOPD for self-management of chronic obstructive pulmonary disease
-
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
-
Antimicrobial prescribing: cefiderocol (ES31)
Summary of the evidence on antimicrobial prescribing: cefiderocol
-
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
-
Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)
Summary of the evidence on antimicrobial prescribing: delafloxacin
-
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)
ES24 . Key messages The content of this evidence review was up-to-date
-
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)
ES25 . Key messages The content of this evidence review was up-to-date on 20 April 2020. See summaries of product characteristics
-
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)
ES26 . Key messages The content of this evidence review was up-to-date on 13 May 2020. See summaries of product characteristics
-
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)
ES23 . Key messages The content of this evidence review was up-to-date
-
COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
ES27 . Key messages The content of this evidence review was up-to-date on 4 June 2020. See summaries of product characteristics
-
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
ES33 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics
-
The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 15 months
NICE indicators. NM15 schizophrenia guidance.
-
The percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months
NICE indicators. NM13 Diabetes foot problems guidance.
-
The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less
NICE indicators. NM01 Diabetes guidance.
-
The proportion of lung cancer cases for which a stage at diagnosis is recorded
The proportion of lung cancer cases for which a stage at diagnosis is recorded Subject(s): Cancer
-
Proportion of pregnant women who were smokers at the time of delivery
Proportion of pregnant women who were smokers at the time of delivery Subject(s): Pregnancy and neonates
-
The proportion of full term births where the child has a low birth weight
The proportion of full term births where the child has a low birth weight Subject(s): Pregnancy and neonates
-
The proportion of births resulting in a neonatal unit admission
The proportion of births resulting in a neonatal unit admission Subject(s): Pregnancy and neonates
-
The proportion of pregnant women having a planned caesarean section who have the procedure carried out at or after 39 weeks 0 days
The proportion of pregnant women having a planned caesarean section who have the procedure carried out at or after 39 weeks 0 days
-
The proportion of babies exclusively or partially breastfed 6 to 8 weeks after birth
The proportion of babies exclusively or partially breastfed 6 to 8 weeks after birth Subject(s): Pregnancy and neonates